Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $3.84 USD
Change Today -0.041 / -1.06%
Volume 97.1K
As of 8:10 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

rosetta genomics ltd (ROSG) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/17/15 - $5.55
52 Week Low
12/9/14 - $2.07
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ROSETTA GENOMICS LTD (ROSG)

Related News

No related news articles were found.

rosetta genomics ltd (ROSG) Related Businessweek News

No Related Businessweek News Found

rosetta genomics ltd (ROSG) Details

Rosetta Genomics Ltd. develops and commercializes microRNAs based diagnostic tests and therapeutics. MicroRNAs are a group of genes that are produced using instructions encoded in DNA. The company offers diagnostic tests, including Rosetta Cancer Origin test, a microRNA-based diagnostic to identify 42 tumor types that include carcinomas, soft tissue tumors, lymphoma, and other malignancies; Rosetta Mesothelioma test to differentiate mesothelioma, a cancer connected to asbestos exposure and other risk factors, from other carcinomas in the lung and pleura; Rosetta Lung Cancer test, a lung cancer classification test for cytology samples; and Rosetta Kidney Cancer test, a microRNA-based kidney tumor classification test for pathology samples. It is also developing a test for the differential diagnosis of indeterminate thyroid fine needle aspirate samples; blood or urine based microRNA biomarkers to develop a diagnostic test for chronic kidney rejection; blood-based microRNA biomarkers to develop a diagnostic test for early diagnosis of heart failure and refined risk stratification of patients following myocardial infarction; tissue-based microRNA biomarkers to develop a test for the risk stratification of patients with non-muscle-invasive bladder cancer; tissue-based microRNA biomarkers to develop a test for the pre-surgical risk stratification of patients with endometrial cancer; and microRNA-based diagnostic test for the early diagnosis of Alzheimer’s disease. The company distributes its products primarily in Australia, Canada, Greece, India, Israel, New Zealand, Qatar, Romania, Saudi Arabia, Singapore, Turkey, and the United Arab Emirates. Rosetta Genomics Ltd. was founded in 2000 and is based in Rehovot, Israel.

52 Employees
Last Reported Date: 03/16/15
Founded in 2000

rosetta genomics ltd (ROSG) Top Compensated Officers

Chief Executive Officer and President
Total Annual Compensation: $800.0K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $141.0K
Chief Medical Officer
Total Annual Compensation: $313.0K
Chief Legal Officer and Secretary
Total Annual Compensation: $273.0K
Chief Scientific Officer
Total Annual Compensation: $163.0K
Compensation as of Fiscal Year 2014.

rosetta genomics ltd (ROSG) Key Developments

Rosetta Genomics Ltd. Launches Two Assays for Bladder Cancer

Rosetta Genomics Ltd. announced that the company will commercially introduce two FGFR3 gene mutation assays; one for diagnostic monitoring using urine samples to detect recurrences of FGFR3-positive low-grade bladder cancers, and the other in conjunction with Ki67 expression for tissue-based prognostication at initial diagnosis of bladder cancer. Both assays will be introduced at the American Urological Association Annual Meeting (AUA 2015) taking place from May 15-19, 2015 in New Orleans. FGFR3 mutation analysis identifies low-grade bladder cancer in both urine- and tissue-based specimens to help urologists better manage patients through improved prognostication and non-invasive recurrence monitoring in urine samples. These assays are used in conjunction with the company's FISH technology to provide highly sensitive and specific assays for all grades of bladder cancer. Multiple prior studies have shown that FGFR3 has the ability to detect a significant number of low-grade bladder tumors as well as tumors in the upper urothelial tract from voided urine specimens. Therefore, FGFR3 may detect tumors that conventional detection methods miss.

Rosetta Genomics Plans to Launch OncoGxOne™

Rosetta Genomics Ltd. announced plans to introduce OncoGxOne™, Admera Health’s next-generation sequencing (NGS) panel that detects a vast number of genetic alterations implicated in cancer to provide clear, concise and actionable clinical recommendations from a single, comprehensive test. OncoGxOne™ was recently approved as a Laboratory Developed Test (LDT) and this launch stems from Rosetta Genomics’ collaboration with Admera Health announced on October 30, 2014. OncoGxOne™ will be the fourth new product introduced by Rosetta Genomics in 2015. OncoGxOne™ interrogates all types of genomic aberrations in 64 genes, specifically 56 related to cancer targeted therapy and 8 related to chemotherapy. This test covers all exons and 5’ and 3’ UTRs for each gene, as well as all introns that harbor potential gene translocation breakpoints. OncoGxOne™ is performed on a modest-sized pathology sample in the standard format of FFPE (formalin fixed paraffin embedded) tissue, the same as Rosetta’s other clinical microRNA-based diagnostics. OncoGxOne™ will compete with currently available genomic profiling offerings through next-generation sequencing platforms that can identify potentially actionable cancer-driving mutations, which can be targeted by specific therapies.

Rosetta Genomics, Ltd. Announces Consolidated Earnings Results for the Year Ended December 31, 2014

Rosetta Genomics, Ltd. announced consolidated earnings results for the year ended December 31, 2014. For the period, the company reported revenue of USD 1,327,000 against USD 405,000 a year ago. Operating loss was USD 14,252,000 against USD 13,347,000 a year ago. Loss before taxes was USD 14,511,000 against USD 13,170,000 a year ago. Loss from continuing operations was USD 14,526,000 against USD 13,170,000 a year ago. Net comprehensive loss after discontinued operations was USD 14,526,000 against USD 12,897,000 a year ago. Basic and diluted net loss per ordinary share from continuing operations was USD 1.29 against USD 1.37 a year ago. Basic and diluted net loss per ordinary share was USD 1.29 against USD 1.34 a year ago. Non-GAAP net loss was USD 13,583,000 or USD 1.21 per basic and diluted share against USD 12,004,000 or USD 1.25 per basic and diluted share a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ROSG:US $3.84 USD -0.041

ROSG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cancer Genetics Inc $10.26 USD -0.17
Genomic Health Inc $27.24 USD +0.13
NeoGenomics Inc $5.23 USD +0.05
Response Genetics Inc $0.36 USD +0.0175
Veracyte Inc $10.69 USD -0.15
View Industry Companies

Industry Analysis


Industry Average

Valuation ROSG Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 34.1x
Price/Book 3.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 22.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ROSETTA GENOMICS LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at